natgillin/translations-raw huggingface dataset:
The suspension contains rapid-acting and intermediate-acting insulin aspart in the ratio 50/50. 
Suspenzija sadrži brzodjelujući i srednjedugodjelujući aspart inzulin u omjeru 50/50.
► Every time you use a new NovoMix 70 Penfill (before you put the cartridge into the insulin delivery system) 
► Svaki puta kad koristite novi NovoMix 70 Penfill (prije nego što uložak stavite u pomagalo za primjenu inzulina)
Other medicines and NovoMix 50 
Drugi lijekovi i NovoMix 50
NovoMix 30 is generally taken immediately before a meal. 
NovoMix 30 se uobičajeno primjenjuje neposredno prije obroka.
Serious allergic reactions to NovoMix 70 or one of its ingredients (called a systemic allergic reaction) is a very rare side effect, but it can potentially be life-threatening. 
Ozbiljna alergijska reakcija na NovoMix 70 ili neki od njegovih sastojaka (naziva se sistemska alergijska reakcija) je vrlo rijetka nuspojava, ali može biti opasna po život.
• There is limited experience with NovoMix 30 in children aged 6-9 years. 
• Iskustvo s lijekom NovoMix 30 u djece u dobi od 6-9 godina ograničeno je.
NovoMix 70 is not to be used in insulin infusion pumps. 
NovoMix 70 se ne smije koristiti u inzulinskim infuzijskim pumpama.
NovoMix 70 will start to lower your blood sugar 10-20 minutes after you inject it, the maximum effect occurs between 1 and 4 hours after the injection, and the effect lasts for up to 14-24 hours. 
NovoMix 70 počinje snižavati razinu šećera u krvi 10-20 minuta nakon što ga injicirate, maksimalan učinak postiže se između 1 i 4 sata nakon injiciranja, a učinak traje do 14-24 sata.
Transfer to NovoMix 50 from other insulin preparations may require adjustment of dose and timing of administration. 
Pri prijelazu s drugih inzulinskih pripravaka na NovoMix 50 možda će biti potrebno prilagoditi dozu i vrijeme primjene.
NovoMix 30 will start to lower your blood sugar 10-20 minutes after you inject it, the maximum effect occurs between 1 and 4 hours after the injection, and the effect lasts for up to 24 hours. 
NovoMix 30 počinje snižavati razinu šećera u krvi 10-20 minuta nakon što ga injicirate, maksimalan učinak postiže se između 1 i 4 sata nakon injiciranja, a učinak traje do 24 sata.
However, the NovoMix 70 dose may need to be adjusted. 
Međutim, možda će biti potrebno prilagoditi dozu lijeka NovoMix 70.
In patients with type 2 diabetes, a dose reduction of 20% is recommended for patients with an HbA1c less than 8% when a GLP-1 receptor agonist is added to NovoMix 30, to minimise the risk of hypoglycaemia. 
Kada se lijeku NovoMix 30 dodaju agonisti GLP-1 receptora u liječenju bolesnika sa šećernom bolešću tipa 2 u kojih je vrijednost HbA1c manja od 8%, preporučuje se smanjenje doze lijeka za 20%
What you need to know before you use NovoMix 30 
Što morate znati prije nego počnete primjenjivati NovoMix 30
NovoMix 50 is not to be used in insulin infusion pumps. 
NovoMix 50 se ne smije koristiti u inzulinskim infuzijskim pumpama.
Serious allergic reactions to NovoMix 30 or one of its ingredients (called a systemic allergic reaction) is a very rare side effect, but it can potentially be life-threatening. 
Ozbiljna alergijska reakcija na NovoMix 30 ili neki od njegovih sastojaka (naziva se sistemska alergijska reakcija) je vrlo rijetka nuspojava, ali može biti opasna po život.
A 16-week clinical trial comparing postprandial glycaemic control of meal-related NovoMix 30 with meal-related human insulin/biphasic human insulin 30 and bedtime NPH insulin was performed in 167 patients aged 10 to 18 years. 
U kliničkom ispitivanju koje je trajalo 16 tjedana postprandijalna regulacija glikemije s lijekom NovoMix 30 primijenjenim uz obrok uspoređena je s humanim inzulinom/bifazičnim humanim inzulinom 30 primijenjenim uz obrok uz NPH inzulin prije spavanja.
NovoMix 30 is not to be used in insulin infusion pumps. 
NovoMix 30 se ne smije koristiti u inzulinskim infuzijskim pumpama.
NovoMix 70 is a biphasic insulin, which contains 70% soluble insulin aspart. 
NovoMix 70 je bifazični inzulin koji sadrži 70% otopine aspart inzulina.
Other medicines and NovoMix 30 
Drugi lijekovi i NovoMix 30
NovoMix 70 has a faster onset of action than biphasic human insulin and should generally be given immediately before a meal. 
NovoMix 70 ima brži početak djelovanja od bifazičnog humanog inzulina i uobičajeno se daje neposredno prije obroka.
• No data are available for NovoMix 30 in children below 6 years of age. 
• Nema dostupnih podataka o lijeku NovoMix 30 u djece mlađe od 6 godina.
• Repeat the rolling and moving procedures (see pictures A and B) until the liquid does appear uniformly white, cloudy and aqueous. 
• Ponovno provaljajte i pomičite uložak (vidjeti slike A i B), sve dok tekućina ne postane jednoliko bijela, zamućena i vodena.
• NovoMix 30 can be used in adolescents and children aged 10 years and above. 
Djeca i adolescenti • NovoMix 30 se može primjenjivati u adolescenata i djece u dobi od 10 ili više godina.
The individual insulin requirement is usually between 0.5 and 1.0 unit/kg/day. 
Individualna potreba za inzulinom obično se kreće u rasponu od 0,5 do 1,0 jedinice/kg/dan, a NovoMix 50 može u potpunosti ili djelomično nadoknaditi tu potrebu.
► Every time you use a new NovoMix 50 Penfill (before you put the cartridge into the insulin delivery system) 
Svaki puta kad koristite novi NovoMix 50 Penfill (prije nego što uložak stavite u pomagalo za primjenu inzulina)
The insulin aspart in the soluble phase of NovoMix 70 comprises 70% of the total insulin; this is absorbed more rapidly from the subcutaneous layer than the soluble insulin component of biphasic human insulin. 
Aspart inzulin u topivoj fazi lijeka NovoMix 70 čini 70% ukupnog inzulina; on se iz supkutanog sloja apsorbira brže nego topiva komponenta bifazičnog humanog inzulina.
The maximum serum insulin concentration is, on average, 50% higher with NovoMix 30 than with biphasic human insulin 30. 
Maksimalna koncentracija inzulina u serumu je prosječno 50% viša kod primjene lijeka NovoMix 30
NovoMix 30 FlexPen EU/1/00/142/009 EU/1/00/142/010 EU/1/00/142/023 EU/1/00/142/024 EU/1/00/142/025 
EU/1/00/142/009 EU/1/00/142/010 EU/1/00/142/023 EU/1/00/142/024 EU/1/00/142/025
Pre-meal blood glucose level 
Vrijednosti glukoze u krvi prije obroka
NovoMix 70 is presented as a suspension for injection. 
NovoMix 70 je suspenzija za injekciju.
► Every time you use a new NovoMix 30 Penfill (before you put the cartridge into the insulin delivery system) 
Svaki puta kad koristite novi NovoMix 30 Penfill (prije nego što uložak stavite u pomagalo za primjenu inzulina)
NovoMix 30 is a biphasic insulin, which contains 30% soluble insulin aspart. 
NovoMix 30 je bifazični inzulin koji sadrži 30% otopine aspart inzulina.
NovoMix 30 Penfill EU/1/00/142/004 EU/1/00/142/005 
EU/1/00/142/004 EU/1/00/142/005
NovoMix 50 is a mixture consisting of 50% soluble insulin aspart and 50% insulin aspart crystallised with protamine. 
NovoMix 50 je mješavina koja se sastoji od 50% otopine aspart inzulina i 50% aspart inzulina kristaliziranog s protaminom.
In healthy volunteers, a mean maximum serum concentration of 140 ± 32 pmol/l was reached about 60 minutes after a subcutaneous dose of 0.20 unit/kg body weight. 
U zdravih dobrovoljaca srednja maksimalna koncentracija u serumu od 140 ± 32 pmol/l postignuta je oko 60 minuta nakon supkutane primjene doze od 0,20 jedinica/kg tjelesne težine.
Important information about some of the ingredients in NovoMix 70 
Važne informacije o nekim sastojcima lijeka NovoMix 70
NovoMix 30 has a faster onset of action than biphasic human insulin and should generally be given immediately before a meal. 
NovoMix 30 ima brži početak djelovanja od bifazičnog humanog inzulina i uobičajeno se daje neposredno prije obroka.
NovoMix 30 FlexPen is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist needles. 
NovoMix 30 FlexPen je napunjena brizgalica (označena bojom) namijenjena uporabi s iglama NovoFine ili NovoTwist.
► If you are treated with NovoMix 30 Penfill and another insulin Penfill cartridge, you should use two insulin delivery systems, one for each type of insulin. 
► Ako se liječite lijekom NovoMix 30 Penfill i još jednim inzulinom u Penfill ulošku, morate koristiti dva pomagala za primjenu inzulina, po jedan za svaku vrstu inzulina.
NovoMix 50 has a faster onset of action than biphasic human insulin and should generally be given immediately before a meal. 
NovoMix 50 ima brži početak djelovanja od bifazičnog humanog inzulina i uobičajeno se daje neposredno prije obroka.
NovoMix 50 is presented as a suspension for injection. 
NovoMix 50 je suspenzija za injekciju.
► If you are treated with NovoMix 50 Penfill and another insulin Penfill cartridge, you should use two insulin delivery systems, one for each type of insulin. 
► Ako se liječite lijekom NovoMix 50 Penfill i još jednim inzulinom u Penfill ulošku, morate koristiti dva pomagala za primjenu inzulina, po jedan za svaku vrstu inzulina.
It is recommended to resuspend the insulin as instructed every time you use a new NovoMix 70 Penfill. 
Preporučljivo je inzulin izmiješati u skladu s uputama svaki puta kad primijenite novi NovoMix 70 Penfill.
The insulin aspart in the soluble phase of NovoMix 50 comprises 50% of the total insulin; this is absorbed more rapidly from the subcutaneous layer than the soluble insulin component of biphasic human insulin. 
Aspart inzulin u topivoj fazi lijeka NovoMix 50 čini 50% ukupnog inzulina; on se iz supkutanog sloja apsorbira brže nego topiva komponenta bifazičnog humanog inzulina.
NovoMix 50 is a biphasic insulin, which contains 50% soluble insulin aspart. 
NovoMix 50 je bifazični inzulin koji sadrži 50% otopine aspart inzulina.
The influence of different injection sites on the absorption of NovoMix 70 has not been investigated. 
Nije ispitivan utjecaj različitih mjesta injiciranja na apsorpciju lijeka NovoMix 70.
NovoMix 70 is for subcutaneous administration only. 
NovoMix 70 je namijenjen samo za supkutanu primjenu.
► If you are treated with NovoMix 70 Penfill and another insulin Penfill cartridge, you should use two insulin delivery systems, one for each type of insulin. 
Ako se liječite lijekom NovoMix 70 Penfill i još jednim inzulinom u Penfill ulošku, morate koristiti dva pomagala za primjenu inzulina, po jedan za svaku vrstu inzulina.
The insulin aspart in the soluble phase of NovoMix 30 comprises 30% of the total insulin; this is absorbed more rapidly from the subcutaneous layer than the soluble insulin component of biphasic human insulin. 
Aspart inzulin u topivoj fazi lijeka NovoMix 30 čini 30% ukupnog inzulina; on se iz supkutanog sloja apsorbira brže nego topiva komponenta bifazičnog humanog inzulina.
Ask your doctor, nurse or pharmacist for advice before taking any medicine while pregnant or breastfeeding. 
Dok ste trudni ili dojite, obratite se svom liječniku, medicinskoj sestri ili ljekarniku za savjet prije nego uzmete bilo koji lijek.
NovoMix 50 must not be administered intravenously, as it may result in severe hypoglycaemia. 
4.4 Posebna upozorenja i mjere opreza pri uporabi NovoMix 50 se ne smije primjenjivati intravenski jer to može rezultirati teškom hipoglikemijom.
There is limited clinical experience with NovoMix 70 in pregnancy. 
Kliničko iskustvo s lijekom NovoMix 70 u trudnoći ograničeno je.
The pharmacokinetics of NovoMix 70 have not been investigated in paediatrics, elderly patients or in patients with renal or hepatic impairment. 
Farmakokinetika lijeka NovoMix 70 nije ispitivana u pedijatrijskoj populaciji, kao niti u starijih bolesnika i bolesnika s oštećenjem bubrega ili jetre.
NovoMix 50 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid-acting and intermediate-acting insulin aspart in the ratio 50/50. 
NovoMix 50 FlexPen je jednokratna napunjena brizgalica označena bojom koja sadrži mješavinu brzodjelujućeg i srednjedugodjelujućeg aspart inzulina u omjeru 50/50.
NovoMix 50 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediateacting effect, in the ratio 50/50. 
NovoMix 50 je moderni inzulin (inzulinski analog) s brzodjelujućim i srednjedugodjelujućim učinkom, u omjeru 50/50.
Important information about some of the ingredients in NovoMix 50 
Važne informacije o nekim sastojcima lijeka NovoMix 50
In healthy volunteers, a mean maximum serum concentration of 445 ± 135 pmol/l was reached about 60 minutes after a subcutaneous dose of 0.30 unit/kg body weight. 
U zdravih dobrovoljaca srednja maksimalna koncentracija u serumu od 445 ± 135 pmol/l postignuta je oko 60 minuta nakon supkutane primjene doze od 0,30 jedinica/kg tjelesne težine.
There is limited clinical experience with NovoMix 50 in pregnancy. 
Kliničko iskustvo s lijekom NovoMix 50 u trudnoći ograničeno je.
The influence of different injection sites on the absorption of NovoMix 50 has not been investigated. 
Nije ispitivan utjecaj različitih mjesta injiciranja na apsorpciju lijeka NovoMix 50.
The suspension contains rapid-acting and intermediate-acting insulin aspart in the ratio 70/30. 
Suspenzija sadrži brzodjelujući i srednjedugodjelujući aspart inzulin u omjeru 70/30.
Always use the dose selector and the pointer to see how many units you have selected before injecting the insulin. 
Prije injiciranja inzulina, uvijek pogledajte izbornik doze i pokazivač kako biste provjerili koliko ste jedinica odabrali.
It may affect more than 1 in 10 people. 
Mogu se javiti u manje od 1 na 100 osoba.
NovoMix 70 FlexPen Glass ball 
NovoMix 70 FlexPen Staklena kuglica
There is limited clinical experience with NovoMix 30 in children aged 6-9 years (see section 5.1). 
Kliničko iskustvo s lijekom NovoMix 30 u djece u dobi 6-9 godina ograničeno je
When necessary, NovoMix 70 can be given soon after a meal. 
Kad je potrebno, NovoMix 70 može se primijeniti ubrzo nakon obroka.
Important information about some of the ingredients in NovoMix 30 
Važne informacije o nekim sastojcima lijeka NovoMix 30
Since NovoMix 70 should be administered in immediate relation to a meal, the rapid onset of action should be considered in patients with concomitant diseases or treatment where a delayed absorption of food might be expected. 
Budući da se NovoMix 70 treba primjenjivati neposredno uz obrok, u bolesnika koji boluju od popratne bolesti ili su podvrgnuti liječenju kod kojeg se može očekivati usporena apsorpcija hrane, potrebno je imati u vidu njegov brz početak djelovanja.
The necessity of resuspending the NovoMix 70 suspension immediately before use is to be stressed to the patient. 
Bolesniku treba naglasiti da je NovoMix 70 potrebno resuspendirati neposredno prije primjene.
The pharmacokinetics of NovoMix 50 have not been investigated in paediatrics, elderly patients or in patients with renal or hepatic impairment. 
Farmakokinetika lijeka NovoMix 50 nije ispitivana u pedijatrijskoj populaciji, kao niti u starijih bolesnika i bolesnika s oštećenjem bubrega ili jetre.
How to use NovoMix 70 
Kako primjenjivati NovoMix 70
The influence of different injection sites on the absorption of NovoMix 30 has not been investigated. 
Nije ispitivan utjecaj različitih mjesta injiciranja na apsorpciju lijeka NovoMix 30.
The pharmacokinetics of NovoMix 30 have not been investigated in elderly patients or in patients with renal or hepatic impairment. 
Farmakokinetika lijeka NovoMix 30 nije ispitivana u starijih bolesnika niti u bolesnika s oštećenjem bubrega ili jetre.
There are no restrictions on treatment with NovoMix 70 during breast-feeding. 
Ne postoje ograničenja za liječenje lijekom NovoMix 70 tijekom dojenja.
On rare occasions, injection site reactions may require discontinuation of NovoMix 70. 
Zbog reakcija na mjestu injiciranja rijetko će biti potrebno prekinuti liječenje lijekom NovoMix 70.
Patients transferred to NovoMix 70 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. 
Bolesnicima koji su prešli na NovoMix 70 s druge vrste inzulina možda će biti potreban veći broj injekcija dnevno ili različita doza nego kod primjene njihovih uobičajenih inzulinskih pripravaka.
NovoMix 70 is for injection under the skin (subcutaneously). 
NovoMix 70 je namijenjen injiciranju pod kožu (supkutano).
NovoMix 50 FlexPen Glass ball 
NovoMix 50 FlexPen Staklena kuglica
The time to maximum concentration is, on average, half of that for biphasic human insulin 30. 
polovicu vremena potrebnog kod primjene bifazičnog humanog inzulina 30.
In healthy volunteers, a mean maximum serum concentration of 645 ± 185 pmol/l was reached about 60 minutes after a subcutaneous dose of 0.30 unit/kg body weight. 
U zdravih dobrovoljaca srednja maksimalna koncentracija u serumu od 645 ± 185 pmol/l postignuta je oko 60 minuta nakon supkutane primjene doze od 0,30 jedinica/kg tjelesne težine.
NovoMix 30 is presented as a suspension for injection. 
NovoMix 30 je suspenzija za injekciju.
NovoMix 70 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediateacting effect, in the ratio 70/30. 
NovoMix 70 je moderni inzulin (inzulinski analog) s brzodjelujućim i srednjedugodjelujućim učinkom, u omjeru 70/30.
NovoMix 50 is a biphasic suspension of 50% soluble insulin aspart (rapid-acting human insulin analogue) and 50% protamine-crystallised insulin aspart (intermediate-acting human insulin analogue). 
NovoMix 50 je bifazična suspenzija sa 50% otopine aspart inzulina (brzodjelujući analog humanog inzulina) i 50% aspart inzulina kristaliziranog s protaminom (srednjedugodjelujući analog humanog inzulina).
NovoMix 70 is a biphasic suspension of the insulin analogue, insulin aspart. 
NovoMix 70 je bifazična suspenzija inzulinskog analoga, aspart inzulina.
Patients transferred to NovoMix 30 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. 
Bolesnicima koji su prešli na NovoMix 30 s druge vrste inzulina možda će biti potreban veći broj injekcija dnevno ili različita doza nego kod primjene njihovih uobičajenih inzulinskih pripravaka.
Patients transferred to NovoMix 50 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. 
Bolesnicima koji su prešli na NovoMix 50 s druge vrste inzulina možda će biti potreban veći broj injekcija dnevno ili različita doza nego kod primjene njihovih uobičajenih inzulinskih pripravaka.
Uncommon - Urticaria, rash, eruptions Very rare - Anaphylactic reactions* 
Manje često - urtikarija, osip, erupcije
On rare occasions, injection site reactions may require discontinuation of NovoMix 50. 
Zbog reakcija na mjestu injiciranja rijetko će biti potrebno prekinuti liječenje lijekom NovoMix 50.
Since NovoMix 50 should be administered in immediate relation to a meal, the rapid onset of action should be considered in patients with concomitant diseases or treatment where a delayed absorption of food might be expected. 
Budući da se NovoMix 50 treba primjenjivati neposredno uz obrok, u bolesnika koji boluju od popratne bolesti ili su podvrgnuti liječenju kod kojeg se može očekivati usporena apsorpcija hrane, potrebno je imati u vidu njegov brz početak djelovanja.
NovoMix 70 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid-acting and intermediate-acting insulin aspart in the ratio 70/30. 
NovoMix 70 FlexPen je jednokratna napunjena brizgalica označena bojom koja sadrži mješavinu brzodjelujućeg i srednjedugodjelujućeg aspart inzulina u omjeru 70/30.
NovoMix 50 is for subcutaneous administration only. 
NovoMix 50 je namijenjen samo za supkutanu primjenu.
The suspension contains rapid-acting and intermediate-acting insulin aspart in the ratio 30/70. 
Suspenzija sadrži brzodjelujući i srednjedugodjelujući aspart inzulin u omjeru 30/70.
There is limited clinical experience with NovoMix 30 in pregnancy. 
Kliničko iskustvo s lijekom NovoMix 30 u trudnoći ograničeno je.
1 x 3 ml pre-filled pen 5 x 3 ml pre-filled pens 10 x 3 ml pre-filled pens 
1 x 3 ml napunjena brizgalica 5 x 3 ml napunjenih brizgalica 10 x 3 ml napunjenih brizgalica
NovoMix 70 is a mixture consisting of 70% soluble insulin aspart and 30% insulin aspart crystallised with protamine. 
NovoMix 70 je mješavina koja se sastoji od 70% otopine aspart inzulina i 30% aspart inzulina kristaliziranog s protaminom.
There are no restrictions on treatment with NovoMix 50 during breast-feeding. 
Ne postoje ograničenja za liječenje lijekom NovoMix 50 tijekom dojenja.
When necessary, NovoMix 50 can be given soon after a meal. 
Kad je potrebno, NovoMix 50 može se primijeniti ubrzo nakon obroka.
NovoMix 30 dose adjustment 
Prilagodba doze lijeka NovoMix 30
Keep the cartridge in the outer carton in order to protect it from light. 
Uložak čuvati u vanjskoj kutiji radi zaštite od svjetlosti.
The necessity of resuspending the NovoMix 50 suspension immediately before use is to be stressed to the patient. 
Bolesniku treba naglasiti da je NovoMix 50 potrebno resuspendirati neposredno prije primjene.
When NovoMix 70 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection. 
Početak djelovanja lijeka NovoMix 70 nakon supkutane injekcije nastupit će unutar 10 do 20 minuta.
It is recommended to resuspend the insulin as instructed every time you use a new NovoMix 50 Penfill. 
Preporučljivo je inzulin izmiješati u skladu s uputama svaki puta kad primijenite novi NovoMix 50 Penfill.
When necessary, NovoMix 30 can be given soon after a meal. 
Kad je potrebno, NovoMix 30 može se primijeniti ubrzo nakon obroka.
NovoMix 30 is a mixture consisting of 30% soluble insulin aspart and 70% insulin aspart crystallised with protamine. 
NovoMix 30 je mješavina koja se sastoji od 30% otopine aspart inzulina i 70% aspart inzulina kristaliziranog s protaminom.
How to use NovoMix 50 
Kako primjenjivati NovoMix 50
How to handle NovoMix 70 FlexPen 
Kako rukovati brizgalicom NovoMix 70 FlexPen
The necessity of resuspending the NovoMix 30 suspension immediately before use is to be stressed to the patient. 
Bolesniku treba naglasiti da je NovoMix 30 potrebno resuspendirati neposredno prije primjene.
NovoMix 50 is a biphasic suspension of the insulin analogue, insulin aspart. 
NovoMix 50 je bifazična suspenzija inzulinskog analoga, aspart inzulina.
NovoMix 30 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid-acting and intermediate-acting insulin aspart in the ratio 30/70. 
NovoMix 30 FlexPen je jednokratna napunjena brizgalica označena bojom koja sadrži mješavinu brzodjelujućeg i srednjedugodjelujućeg aspart inzulina u omjeru 30/70.
NovoMix 50 is for injection under the skin (subcutaneously). 
NovoMix 50 je namijenjen injiciranju pod kožu (supkutano).
When NovoMix 50 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection. 
Početak djelovanja lijeka NovoMix 50 nakon supkutane injekcije nastupit će unutar 10 do 20 minuta.
There are no restrictions on treatment with NovoMix 30 during breast-feeding. 
Ne postoje ograničenja za liječenje lijekom NovoMix 30 tijekom dojenja.
Since NovoMix 30 should be administered in immediate relation to a meal, the rapid onset of action should be considered in patients with concomitant diseases or treatment where a delayed absorption of food might be expected. 
Budući da se NovoMix 30 treba primjenjivati neposredno uz obrok, u bolesnika koji boluju od popratne bolesti ili su podvrgnuti liječenju kod kojeg se može očekivati usporena apsorpcija hrane, potrebno je imati u vidu njegov brz početak djelovanja.
NovoMix 70 FlexPen is only suitable for subcutaneous injections. 
NovoMix 70 FlexPen je prikladan samo za supkutane injekcije.
NovoMix 30 is for injection under the skin (subcutaneously). 
NovoMix 30 je namijenjen injiciranju pod kožu (supkutano).
NovoMix 50 FlexPen is only suitable for subcutaneous injections. 
NovoMix 50 FlexPen je prikladan samo za supkutane injekcije.
► After each injection, be sure to remove and discard the needle and store NovoMix 70 without the needle attached. 
Nakon svakog injiciranja iglu uvijek skinite i bacite u otpad, a potom spremite NovoMix 70 bez nataknute igle.